PASITHEA THERAPEUTICS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
PASITHEA THERAPEUTICS CORP. (KTTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.61% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-30
- PASITHEA THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.44%.
- PASITHEA THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.61%, a 14.05% decline from fiscal 2024.
- PASITHEA THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 2.44% increase from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.10%, a 24.24% increase from fiscal 2022.
- PASITHEA THERAPEUTICS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.30%, a 153.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 3.61% 10-K · filed 2026-03-30 | ||||
| 2024-12-31 | 4.20% 10-K · filed 2026-03-30 | ||||
| 2023-12-31 | 4.10% 10-K · filed 2025-03-24 | ||||
| 2022-12-31 | 3.30% 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | 3.20% 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | 3.20% 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | 1.44% 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | 1.30% 10-K · filed 2023-03-30 | 1.29% 10-K · filed 2022-03-30 | |||
| 2021-09-30 | 1.29% 10-Q · filed 2021-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |